scholarly journals Four Case Reports of Acute Psychosis Secondary to Low Doses of Prednisone/Prednisolone

Cureus ◽  
2021 ◽  
Author(s):  
Aquila Lesko ◽  
Naciye Kalafat ◽  
Maleeha Afreen
Keyword(s):  
Case Reports ◽  
Low Doses ◽  
Acute Psychosis

Zolpidem withdrawal delirium, seizure, and acute psychosis: Case reports and literature review

2011 ◽  
Vol 16 (4) ◽  
pp. 330-338 ◽  
Author(s):  
Chia-Chang Chien ◽  
Hsien-Te Huanga ◽  
For-Wey Lung ◽  
Chi-Hung Lin
Keyword(s):  
Literature Review ◽  
Case Reports ◽  
Acute Psychosis

Acute Psychosis in Chronic Renal Failure: Case Reports

1974 ◽  
Vol 139 (8) ◽  
pp. 622-624 ◽  
Author(s):  
Richard H. Merrill ◽  
James L. Collins
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Case Reports ◽  
Acute Psychosis

scholarly journals Acute Psychosis in a Child with Severe Dengue

2018 ◽  
Vol 37 (3) ◽  
pp. 273-275
Author(s):  
Ruchika Bhatnagar ◽  
Premlochan Prasad
Keyword(s):  
Psychiatric Symptoms ◽  
Case Reports ◽  
Neuropsychiatric Symptoms ◽  
Adult Population ◽  
Febrile Illness ◽  
Recovery Phase ◽  
Severe Dengue ◽  
Age Group ◽  
Acute Psychosis ◽  
Pediatric Age Group

Dengue fever is emerging as an important cause of acute febrile illness with neuropsychiatric symptoms in adult population especially in endemic areas. Numerous case reports and review articles have already been published in past emphasizing on neurological manifestations in dengue but sufficient data on psychiatric symptoms in pediatric age group is still lacking. Acute psychosis in recovery phase of severe dengue is an uncommon phenomenon, thus rarely reported.

scholarly journals Cariprazine Use in Early Psychosis: Three Case Reports

2021 ◽  
Vol 12 ◽  
Author(s):  
Ricardo Coentre ◽  
Rodrigo Saraiva ◽  
Carolina Sereijo ◽  
Pedro Levy
Keyword(s):  
Atypical Antipsychotic ◽  
Negative Symptoms ◽  
Case Reports ◽  
First Episode Psychosis ◽  
Early Psychosis ◽  
First Episode ◽  
Low Doses ◽  
Bipolar I Disorder ◽  
Episode Psychosis ◽  
Depressive Episodes

Objective: Cariprazine is a new atypical antipsychotic approved for the acute and maintenance treatment of schizophrenia (1, 2) and for the treatment of manic or mixed episodes associated with bipolar I disorder (1). Recently, cariprazine also got extended FDA-approval for the treatment of depressive episodes in adults with bipolar I disorder (3). The use of low doses of atypical antipsychotics is an essential component of early intervention in psychosis. For its particular performance and tolerability, cariprazine is becoming an important option for the treatment of first-episode psychosis.Method: Three patients experiencing first-episode psychosis (FEP) were successfully treated with cariprazine. Two patients were in their first months of the disease, and the third patient was in his third year after the FEP.Results: The three patients had a diagnosis of non-affective FEP, which includes schizophrenia, delusional disorder, and schizoaffective disorder. One of them was in their third year after the FEP with a predominance of negative symptoms at this stage of the disorder. All the patients were treated with cariprazine with a target dose of 3–4.5 mg/day. The three patients showed improvements in their psychosis, including a decrease in negative symptoms. No significant side effects were reported.Conclusion: Our three case reports indicate that cariprazine is an atypical antipsychotic beneficial in the treatment of early psychosis. Treatment with low doses of cariprazine could be effective and tolerable in this phase of the disorder. Future studies with longer follow-up of FEP patients are recommended to confirm these positive results of cariprazine in the early phases of psychosis.

scholarly journals MON-684 Neuroglycopenia: Avoiding Bias in Patients with Acute Psychosis

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Gene Chibuchim Otuonye ◽  
Otto Gibbs ◽  
Rani Delraj Sittol ◽  
Matthew V Tavares ◽  
Munder Abuaisha ◽  
...  
Keyword(s):  
Psychotic Disorders ◽  
Psychiatric Patients ◽  
Case Reports ◽  
Oral Intake ◽  
Glucose Deprivation ◽  
Direct Result ◽  
Psychotic Symptoms ◽  
Acute Psychosis ◽  
Diagnostic Uncertainty ◽  
High Index Of Suspicion

Abstract Introduction The neurogenic response to hypoglycemia (HG) is well established. In contrast, neuroglycopenic (NG) manifestations are widely variable and have been erroneously attributed to other diagnoses. Compounding diagnostic uncertainty is the incidence of these symptoms in a patient with a psychiatric illness. Clinical Case A 51 year old male with hypertension and schizophrenia maintained on amlodipine, risperidone and benztropine was transported to the ER psychiatric unit by law enforcement. He was detained after he was found wandering the streets demonstrating increased verbal and physical aggressiveness. He was known to the unit, with previous admissions for psychosis secondary to schizophrenia. On presentation vitals were solely significant for tachycardia. Physical and mental status examination revealed a disheveled, agitated and combative male who was disoriented to time, person and location. He was actively experiencing visual and auditory hallucinations with psychomotor agitation, intermittent loosening of association, circumstantial speech and persecutory delusions. Initially given one dose of i.m. haloperidol and benztropine, his psychosis persisted. Biochemical investigations were significant for a glucose of 37 mg/dL; All others including alcohol level, toxicology and TSH were normal. Head CT was unremarkable. His HG was treated with i.v. dextrose with complete resolution of psychotic symptoms within one hour of normoglycemia. He needed no further antipsychotic doses save his maintenance risperidone. Further historical enquiry revealed a recent diagnosis of type 2 DM managed on metformin and glimepiride with poor oral intake. He was discharged on metformin and sitagliptin post extensive DM self-management education, h; glimepiride was discontinued. Discussion NG manifestations of hypoglycemia are the direct result of central nervous system glucose deprivation. Uncommonly, they can be the sole presenting complaint in the HG patient. In one study, 27% of patients with insulinomas had only NG symptoms [1]. Interestingly, some case reports suggest acute psychosis may be an important NG feature [2]. Psychiatric patients, particularly those with primary psychotic disorders often face a labyrinthine process when seeking emergent medical care including but not limited to anchoring and ascertainment physician bias. If unrecognized, HG can lead to neuronal death. Clinicians must maintain a high index of suspicion of HG in patients presenting with acute psychosis even in the presence of functional illness so as to reduce morbidity, mortality and medicolegal risk. References Dizon AM., Kowalyk S., Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas, Am J Med. 1999 Mar; 106(3):307-10. Klemen P., Grmec S., Cander, D. Hypoglycemia masquerading as acute psychosis in young age. Crit Care. 2000; 4(Suppl 1): P172. doi: 10.1186/cc892.

The Response of Testes Cells to Low Level, Single dose Helium Particle Irradiation

1982 ◽  
Vol 40 ◽  
pp. 252-253
Author(s):  
D.E. Philpott ◽  
W. Sapp ◽  
C. Williams ◽  
J. Stevenson ◽  
S. Black ◽  
...  
Keyword(s):  
Stem Cell ◽  
Single Dose ◽  
B Cell ◽  
Cell Survival ◽  
Spermatogonial Stem Cell ◽  
Low Doses ◽  
Particle Irradiation ◽  
Stem Cell Survival ◽  
Irradiation Injury ◽  
Radio Sensitivity

Spermatogonial stem-cell survival after irradiation injury has been studied in rodents by histological counts of surviving cells. Many studies, including previous work from our laboratory, show that the spermatogonial population demonstrates a heterogeneous response to irradiation. The spermatogonia increase in radio-sensitivity as differentiation proceeds through the sequence As - Apr - A1 - A2 - A3 - A4 - In - B. The stem (As) cell is the most resistant and the B cell is the most sensitive. The purpose of this work is to investigate the response of spermatogonial cell to low doses (less than 10 0 rads) of helium particle irradiation.

Potentiation of bromotrichloromethane hepatotoxicity in male rats exposed to 10 ppm dietary chlordecone: Electron Microscopic and biochemical study

1990 ◽  
Vol 48 (3) ◽  
pp. 284-285
Author(s):  
O. M. Faroon ◽  
R. W. Henry ◽  
M. G. Soni ◽  
H. M. Mehendale
Keyword(s):  
Free Radical ◽  
Biochemical Study ◽  
Prior Exposure ◽  
Male Rats ◽  
Cellular Injury ◽  
Low Doses ◽  
Mixed Function Oxidase ◽  
Electron Microscopic ◽  
Potent Inducer ◽  
Cellular Energy

Previous work has shown that mirex undergoes photolytic dechlorination to chlordecone (CD) (KeponeR) in the environment. Much work has shown that prior exposure to nontoxic levels of CD causes potentiation of hepatotoxicity and lethality of CCl4, BrCCl3 and other halomethane compounds. Potentiation of bromotrichloromethane hepatotoxicity has been associated with compounds that stimulate the activity of hepatic mixed-function oxidase (MFO). An increase in the metabolism of halomethane by the MFO to a free radical initiates peroxidative decomposition of membranal lipids ending in massive cellular injury. However, not all MFO inducers potentiate BrCCl3 hepatotoxicity. Potentiation by much larger doses of phenobarbital is minimal and th at by a more potent inducer of MFO, mirex, is negligible at low doses. We suggest that the CD and bromotrichloromethane interaction results in a depletion of cellular energy and thereby reducing the cellular ability to undergo mitosis.

Case Reports Link ADHD Stimulants to Skin Eruptions

2011 ◽  
Vol 45 (12) ◽  
pp. 10
Author(s):  
SHERRY BOSCHERT
Keyword(s):  
Case Reports
Sign in / Sign up

Export Citation Format

Share Document